Repligen Corp. 10-Q Summary: Quarter Ended December 31, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2001, and the nine-month period ended on that date. Repligen Corporation operates in two primary areas: the development of therapeutic products for pediatric diseases (autism, mitochondrial disease, autoimmune disorders) and the manufacturing of Protein A products for antibody purification. The company is currently developing lead candidates including secretin for autism, CTLA4-Ig for stem cell transplantation, and uridine for mitochondrial disease.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2001 | Nine Months Ended Dec 31, 2001 |
|---|---|---|
| Total Revenues | $1,179,892 | $2,779,160 |
| Net Loss | $(817,319) | $(3,537,699) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.13) |
| Product Gross Margin | 50% | 46% |
| Cash and Cash Equivalents | $5,708,023 (as of Dec 31, 2001) | |
| Total Marketable Securities | ||
| Total Current Assets | $21,691,888 | |
| Total Current Liabilities | $1,346,537 | |
| Working Capital | $20,345,351 |
Liquidity: Total cash, cash equivalents, and marketable securities totaled approximately $25.5 million at December 31, 2001. The company reported a net cash outflow from operating activities of $3.76 million for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 91% ($562,000) for the three-month period and 68% ($1.12 million) for the nine-month period compared to the same periods in 2000. This growth is primarily driven by increased shipments of Protein A products to Amersham Pharmacia Biotech and other monoclonal antibody producers.
- Expense Reduction: Total costs and expenses decreased 18% for the quarter and increased only 3% for the nine-month period. Research and development expenses dropped 43% for the quarter and 10% for the nine-month period due to reduced clinical trial costs.
- Improved Margins: Product gross margins improved to 50% for the quarter and 46% for the nine-month period, up from 36% in the prior year periods, attributed to product mix and manufacturing efficiencies.
- Investment Income Decline: Investment and interest income decreased 52% for the quarter and 44% for the nine-month period due to lower interest rates and reduced average funds available for investment.
Outlook, Risks, and Management Commentary
Outlook and Capital Resources: Management believes current funding is sufficient to meet working capital and capital expenditure requirements for the next 24 months. The company is constructing a new 25,000-square-foot corporate headquarters in Waltham, Massachusetts, with relocation planned for the first quarter of fiscal 2003. A $500,000 letter of credit has been issued for this lease, collateralized by restricted cash.
Clinical Pipeline:
- Secretin (Autism): Phase 2 results showed statistically significant improvements in a subgroup of patients. Phase 3 trials are planned for 2002 pending FDA approval.
- CTLA4-Ig: Phase 1 safety trials in normal adults were completed with no serious adverse events. A Phase 1/2 trial for autoimmune thrombocytopenic purpura (ITP) is planned in the UK.
- Uridine (Mitochondrial Disease): Phase 1 studies showed symptom improvements. A Phase 2 protocol is being prepared.
Risks and Contingencies:
- Legal Proceedings: Pro-Neuron, Inc. has sued Repligen and UCSD to void a license agreement regarding uridine technology. Repligen intends to defend vigorously. Additionally, Repligen is involved in litigation with Bristol-Myers Squibb regarding patent inventorship for CTLA4 technology.
- Regulatory Approval: There is no assurance that the FDA will approve the synthetic secretin products (SecreFlo and SecreFlux) or future therapeutic candidates.
- Customer Concentration: Two customers accounted for 74% of revenues in the quarter ended December 31, 2001. One customer accounted for 89% of accounts receivable.
Investor Verification Checklist
- Verify the status of the FDA review for SecreFlo and SecreFlux, as approval is required for future milestone payments and royalties.
- Monitor the outcome of the Pro-Neuron, Inc. lawsuit regarding the UCSD uridine license, which could impact the mitochondrial disease pipeline.
- Assess the timeline and cost overruns associated with the new Waltham, Massachusetts facility construction and relocation.
- Review the concentration risk regarding the top two customers who generated 74% of recent revenues.
- Confirm the initiation dates for the planned Phase 3 secretin trials and Phase 1/2 CTLA4-Ig trials.